FEV1 · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with bronchiectasis
Hypertonic saline showed no clear difference in adverse events compared with isotonic saline; GRADE not reported.
1 finding from 1 review
All‐cause mortality · people with bronchiectasis
1 finding from 1 review
Symptoms: cough, sputum volume and ease of expectoration, wheeze, dyspnoea · people with bronchiectasis
1 finding from 1 review
FEV1 (L) · people with bronchiectasis
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
1 finding from 1 review
Frequency and duration of exacerbations · people with bronchiectasis
1 finding from 1 review
Hospital admissions · people with bronchiectasis
1 finding from 1 review
Length of hospital stay · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Adverse events Assessed by investigators or reported by parents · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Clinical severity score (post‐treatment) at day 1 · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Clinical severity score (post‐treatment) at day 2 · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Clinical severity score (post‐treatment) at day 3 · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Annual hospitalisation rates · infants up to 24 months of age with acute bronchiolitis
Nebulised hypertonic saline may leads to lower rate of hospitalisation compared with nebulised 0.9% saline (low certainty).
1 finding from 1 review
Hospital readmission · infants up to 24 months of age with acute bronchiolitis
Nebulised hypertonic saline showed no clear difference in rate of readmission to hospital compared with nebulised 0.9% saline (low certainty).
1 finding from 1 review
Number of days to resolution of symptoms and signs (wheezing) · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Number of days to resolution of symptoms and signs (cough) · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Number of days to resolution of symptoms and signs(pulmonary moist crackles) · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 · adults and children with cystic fibrosis
1 finding from 1 review